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ABSTRACT
Telomerase, a ribonucleoprotein (RNP) complex, is a type of RNA-dependent DNA polymerase that synthesises telomeric 
DNA repeats (TTAGGG) at the 3’ end of chromosomes. Most of the cancer cells express high level of telomerase which 
results in cellular immortality. The high telomerase activity in cancer cells can be detected via expression of human TERT 
(hTERT), the catalytic protein subunit of telomerase, and expression of human TERC (hTERC), the RNA component 
in telomerase. Boldine, a natural alkaloid compound, was shown to have anticancer properties on various types of 
cancer cells, but the anti-telomerase property was poorly understood. This study was carried out to investigate the 
ability of boldine in targeting telomerase on the human colon cancer cell line, HCT 116, by analyzing the expression 
of hTERT and hTERC. Boldine was shown to have a time- and dose-dependent cytotoxic effect on HCT 116 cell line 
in SRB assay. The protein expression of hTERT was assessed through Western blot where it was observed to be down-
regulated upon boldine treatment compared to control. The cells treated with boldine also exhibited a down-regulation 
of mRNA expression for both hTERT and hTERC in Real Time PCR (qRT-PCR). The down-regulation of hTERT protein 
expression correlated with the reduced hTERC mRNA expression in qRT-PCR. The observations on the down-regulation 
of protein and mRNA expressions of telomerase related genes, hTERT and hTERC, in this study suggested that boldine 
might become a significant candidate for telomerase-targeted anti-cancer therapy.
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ABSTRAK
Telomerase, iaitu satu kompleks ribonukleoprotein (RNP) merupakan sejenis DNA polimerase bersandar RNA yang 
mensintesis telomerik DNA berulangan (TTAGGG) pada hujung kromosom. Kebanyakan sel kanser mengekspres 
telomerase pada tahap yang tinggi dan akan mengakibatkan sel mencapai keabadian. Aktiviti telomerase yang tinggi 
dalam sel kanser dapat dikesan melalui pengekspresan TERT manusia (hTERT) iaitu subunit protein katalitik telomerase 
dan pengekspresan TERC manusia (hTERC) iaitu komponen RNA dalam telomerase. Boldina merupakan sebatian alkaloid 
semula jadi yang mempunyai sifat antikanser terhadap pelbagai jenis sel kanser, namun begitu sifat anti-telomerase 
masih kurang difahami. Kajian ini dijalankan untuk mengkaji keupayaan boldina untuk mensasarkan telomerase dalam 
titisan sel kanser kolon manusia, HCT 116 dengan menganalisis pengekspresan hTERT dan hTERC. Boldina dikatakan 
mempunyai kesan sitotoksik yang bersandar kepada masa and dos terhadap titisan sel HCT 116 dalam asai SRB. 
Pengekspresan protein hTERT telah dinilai melalui Western blot dengan pengawalaturannya menurun selepas rawatan 
dengan boldina berbanding kawalan. Sel yang dirawat dengan boldina juga menunjukkan pengawalaturan yang menurun 
bagi pengekspresan mRNA untuk kedua-dua hTERT dan hTERC melalui PCR masa sebenar (qRT-PCR). Pengawalaturan 
yang menurun bagi pengekspresan protein hTERT didapati berkorelasi dengan pengurangan pengekspresan mRNA 
hTERC melalui qRT-PCR. Pemerhatian terhadap pengawalaturan yang menurun bagi pengekspresan protein dan mRNA 
gen berkait telomerase, hTERT dan hTERC dalam kajian ini mencadangkan bahawa boldina berkemungkinan menjadi 
calon penting untuk terapi antikanser yang mensasarkan telomerase.
Kata kunci: Boldina; hTERC; hTERT; kanser; telomerase
INTRODUCTION
Telomerase is an enzyme which synthesises telomeric DNA 
repeats in order to maintain telomere length. Telomerase 
was found to be highly expressed in various cancer 
cells (Fernández-Marcelo et al. 2015; Jafri et al. 2016). 
Telomerase is crucial in the immortalization of cancer 
cells to reverse the loss of telomere in every round of cell 
division (Cong et al. 2002; Xu et al. 2016). High telomerase 
activity was observed in colon cancer cells, suggesting 
that colon cancer cells required telomerase to proliferate 
indefinitely and escape from replicative senescence 
(Aljarbou et al. 2018; Ayiomamitis et al. 2014; Bertorelle 
et al. 2014; Chadeneau et al. 1995). The high telomerase 
activity in cancer cells can be detected via the expression 
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of hTERT, the protein catalytic subunit of telomerase, and 
hTERC, the RNA component in telomerase (Beattie et al. 
1998; Herbert et al. 1999; Ishikawa 1997; Weinrich et al. 
1997). Cancer cells achieved proliferative immortality 
usually by up-regulating the hTERT and hTERC gene 
expression in telomerase (Akıncılar et al. 2015; Cristofari 
et al. 2006; Leão et al. 2018; Xi et al. 2014). Thus, targeting 
the hTERT and hTERC in telomerase could be a promising 
approach for telomerase-based cancer therapies.
 Boldine, a natural compound obtained from Boldo 
tree, was shown to inhibit telomerase activity mainly by 
down-regulating the expression of hTERT in various cancer 
cells. For instance, boldine suppressed the proliferation of 
two telomerase-positive breast cancer cells, MCF-7 and 
MDA-MB-231, by inhibiting the telomerase activity in 
both cancer cell lines. The telomerase inhibition was 
proven to occur via down-regulation of hTERT (Noureini 
et al. 2015). Boldine also showed cytotoxic effect in 
HepG-2 cells where boldine suppressed the immortality 
of HepG-2 cells through telomerase inhibition (Noureini 
et al. 2015a). Although boldine has been used to test on 
several cancer cells type such as embryonic kidney cells 
HEK293, human hepatocellular carcinoma cell line HepG-
2 and breast cancer MCF-7, there is still no study reported 
on the effect of boldine on human colon cancer cell line 
HCT 116. Besides, boldine showed to have no toxic effect 
on non-cancer cells when used at the same concentrations 
as those used on cancer cells, and thus may be a promising 
compound as an anti-cancer agent in treatment of human 
cancer. However, limited work has been carried out on the 
ability of boldine to inhibit telomerase activity in human 
colon cancer cells as well as down-regulation of telomerase 
related genes especially hTERC gene. 
 In the present study, evidence of telomerase-based 
cancer therapeutic potential of boldine as a cytotoxic 
agent in the human colon cancer cell line, HCT 116 was 
investigated. Accordingly, the cytotoxicity of boldine on 
HCT 116 cell line was identified in this study. The effect 
of boldine on hTERT protein expression in HCT 116 cells 
was determined. qRT-PCR was also carried out to assess 
mRNA expression of hTERT and hTERC genes in HCT 
116 cell line.
MATERIALS AND METHODS
CELL CULTURE AND COMPOUND
Human Colon Carcinoma (HCT 116) cell line was 
purchased from the American Type Culture Collection 
(ATCC, USA). HCT 116 was cultured as monolayers in 
RPMI 1640 (Nacalai Tesque, Japan) supplemented with 
10% heat-inactivated fetal bovine serum (FBS; Sigma, 
USA), 1% penicillin/streptomycin (Nacalai Tesque, Japan), 
and 1% amphotericin B (250 μg/mL; Sigma, USA). The 
cells were maintained in a humidified incubator (ESCO) 
with 95% air and 5% of CO2 at 37°C. Boldine 99% was 
obtained from Sigma (Singapore) and the compound was 
dissolved in DMSO (Nacalai Tesque, Japan).
CYTOTOXIC ASSAY
Cells were seeded (5000 cells/well) into sterile 96-well 
micro titer plates in growth medium. The cells were 
allowed to proliferate in a 5% CO2 incubator at 37°C and 
were cultured overnight to allow cell attachment. After 
overnight incubation, serial dilution of boldine was carried 
out to obtain different boldine concentrations (0, 3.13, 6.25, 
12.5, 25, 50 and 100 μg/mL). The cells were treated with 
boldine for three different time points at 24, 48 and 72 h. 
Untreated cells were referred to the well with only the cells 
and the media, which served as a control. 
 Sulphorhodamine B (SRB) assay was carried out to 
measure the viability of the cells upon boldine treatment. 
Cell viability was assessed based on the measurement of 
the total protein content of viable cells (Houghton et al. 
2007). Upon each incubation period (24, 48 and 72 h), 
50 μL of 40% ice-cold trichloroacetic acid (TCA; Merck, 
Germany) was added to each of the well to fix the cells, 
and the plate was incubated for an hour at 4oC. The cells 
were then washed, followed by the addition of 0.4% SRB 
dye (Sigma-Aldrich, USA) to each of the well. The plate 
was incubated for 30 min at room temperature for staining 
process. After incubation period, they were then washed 
with 100 μL of 1% acetic acid (Merck, Germany) to remove 
any unbound dye. In order to solubilize the bound SRB 
stain, 100 μL of 10 mM Tris buffer with pH10.5 (Merck, 
Germany) was added and the plate was left to shake at 
500 rpm for 5 min using plate shaker (Thermo Fisher, 
Latvia). Absorbance of the dye was measured at 492 nm 
using a plate reader (BioTek, USA). All experiments were 
performed in triplicates. The results were presented as 
means ± SD. 
 The IC50 values of boldine at 24, 48, and 72 h were 
determined from the dose-response curves. The percentage 
of cell viability of each of the cells treated with various 
concentrations of boldine was calculated accordingly using 
the following formula: 
 Percentage cell viability (%) =  × 100%
with OD control is the absorbance of negative control; and 
OD sample with the absorbance of sample
 The lowest IC50 value of boldine against HCT 116 cell 
line was chosen for subsequent experiment. Cells were then 
plated in six T25 flasks and allowed to adhere overnight. 
The next day, three flasks containing cultured cells were 
treated with the identified concentration of boldine (in 
SRB assay) while another three flasks were left untreated 
to serve as control. These cells were kept in a 5% CO2 
incubator at 37°C for the time period that give the lowest 
IC50 value in SRB assay, which is 72 h.
WESTERN BLOT ANALYSIS
Cells seeded at 2×106 cells per T25 flask were treated 
with the identified concentration of boldine initially 
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for 72 h upon overnight incubation. At the end of the 
treatment, the cells were collected. Cell scrapper was 
used to scrap all the cells in the flask, and the detached 
cells were collected into a falcon tube. The cells were 
washed with 1× phosphate buffer saline (PBS; Nacalai 
Tesque, Japan) twice. After centrifuged, the supernatant 
in the falcon tube was removed. Cells pellet were then 
added with Radioimmunoprecipitation assay (RIPA) 
buffer (Sigma-Aldrich, USA) containing 1% of protease 
inhibitor (Sigma-Aldrich, USA) and was incubated in ice 
for 30 min. Upon incubation period, the cell lysate was 
centrifuged at 14,000 rpm for 30 min at 4°C (Thermo 
Scientific™ Heraeus™ Pico™ 17 Microcentrifuge). The 
supernatant (protein) was transferred into Protein LoBind 
tube (Eppendorf) and protein concentration was estimated 
using Bradford assay (Bio-Rad, United States).
 For Western blotting, each sample was prepared 
by mixing the protein samples with loading buffer in 
3:1 ratio. All the protein samples were then boiled on a 
heating block (QBD2-Grant, England) at 70°C for 10 min. 
Western blotting was done using sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) with 
12% acrylamide gel, which is suitable for protein range 
at 10-200 kDa as the hTERT protein is about 126 kDa. 
Pre-stained protein ladder (GeneDireX, USA) was used as 
a marker. A total of 50 μg of protein samples were loaded 
in each well accordingly for electrophoresis. The gels were 
then electro-transferred onto nitrocellulose membrane 
using the transfer apparatus, Mini-PROTEAN® Tetra 
System (Bio-Rad, USA) for 2 h at 90 V. The nitrocellulose 
membrane was blocked with Blocking One (Nacalai 
Tesque, USA). For detection of housekeeping protein, a 
primary anti β-Actin antibody from rabbit (Cell Signalling 
Technology, USA) was used. In detecting hTERT protein, 
the primary anti-hTERT antibody from rabbit (Sigma-
Aldrich, USA) was used. Both primary antibodies were 
diluted in 1:1000 ratio of primary antibody: blocking 
buffer. The membranes were incubated with primary 
antibody overnight at 4°C. After incubation, the 
membranes were washed five times with Tris buffered 
saline containing 0.1% of Tween 20 (TBS-T; Sigma, 
USA) for 5 min each. The membranes were then incubated 
with secondary antibody for 1 h at room temperature 
and washed five times with TBS-T for 5 min each. The 
secondary antibody used for both hTERT and β-Actin was 
anti-rabbit antibody (Cell Signaling Technology, USA) 
conjugated with reporter enzyme-horseradish peroxidase 
(HRP) which was prepared in 1:10000 ratio of secondary 
antibody: blocking buffer. The results were detected using 
an enhanced chemiluminescence reagent (luminol and 
stable peroxide solution with ratio 1:1) from Western 
Bright™ ECL (Advansta, USA) under gel documentation 
camera. The intensity of bands was quantified using 
ImageJ program.
REAL-TIME POLYMERASE CHAIN REACTION (qRT-PCR)
Total RNA from both boldine-treated and untreated cells 
were extracted using the ReliaPrep RNA Cell Miniprep 
System (Promega, USA) following the manufacturer’s 
protocol. Initially, both boldine-treated and untreated cells 
were collected and the cells were centrifuged at 300 g for 
5 min and the supernatant was removed. Cell pellet was 
washed with ice-cold, sterile 1× PBS and was pelleted 
again. Lysis buffer was then added to the cell pellet in 
order to lyse the cells. Upon transferring cell lysate 
to Minicolumn and centrifuged at high speed, DNase 
treatment was performed to remove any residual DNA in 
the sample. Then, the columns were washed repeatedly 
and lastly, nuclease free water was added to elute the 
RNA. Samples containing RNA were stored at -80°C.
 The concentration of RNA samples was quantified 
using Take 3 Micro-Volume Plate (BioTek, USA). 
The values of the A260/A280 and A260/A230 ratios of RNA 
samples were identified to ensure the purity of RNA. To 
assess the integrity of RNA, a total of 500 ng of the RNA 
samples containing RNA loading dye were run beside 2 
μL RiboRuler™ High Range RNA Ladder (Fermentas, 
Lithuania) on a 1% agarose gel stained with ethidium 
bromide (EtBr) at 60 V for 45 min. The gel was viewed 
under gel documentation camera.
 Complementary DNA was synthesized with 
GoScript™ Reverse Transcription System (Promega, 
USA). An aliquot of 2 μg of total RNA was reverse-
transcribed by GoScript™ Reverse Transcriptase using 
Oligo(dT)15 primers and random primers according to the 
manufacturer’s protocol. The real-time PCR for individual 
gene expression analysis was performed using Applied 
Biosystems StepOnePlus™ Real-Time PCR System. 
Relative expression levels of hTERT and hTERC were 
measured using TaqMan® Gene Expression Master Mix 
(Applied Biosystems, USA) and specific Taqman probes 
(Applied Biosystems, USA). The reaction conditions for 
all amplicons were as follows: 95°C for 20 s, followed by 
40 cycles at 95°C for 1 s, 60°C for 20 s. Data were then 
collected and analysed using StepOne™ Software v2.2.2. 
Ct values were normalized to the housekeeping gene, 
β-Actin. The relative gene expression was calculated 
using the 2-ΔΔCt formula.
STATISTICAL ANALYSIS
Data were expressed as mean ± SD of triplicates. Graph 
was plotted using three technical replicates, n=3 for the 
IC50 value of boldine on HCT 116 with standard deviation 
(SD). The significant values (compared to control) were 
determined by one-way ANOVA using SPSS Statistics 
22. Data of Western Blot and qRT-PCR were analyzed for 
significant difference using unpaired student’s T-test. The 
number of replicates (n) was 3 for each of the experiments. 
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Differences among groups were considered significant at 
p < 0.05. The following notion was used: * indicated p < 
0.05 compared to the non-treated group.
RESULTS 
BOLDINE INHIBITS VIABILITY OF HCT 116 CELLS
The viability of HCT116 cells treated with various 
concentrations of boldine (0 to 100 μg/mL) for 24, 48 and 
72 h were examined using the SRB assay which showed 
that boldine significantly inhibited the growth of HCT 116 
cells in a time- and dose- dependent manner (p < 0.01) 
(Figure 1). In particular, exposure to boldine treatment for 
24 h significantly reduced the percentage of viable cells, 
ranging from 84.2% to 47.3% (Figure 1(A)). Boldine 
showed the maximum effect against HCT 116 cells by 
increasing percentage of inhibition to 81.5% after 48 h and 
to 94.4% after 72 h, respectively, compared to untreated cells 
(Figures 1(B) and 1(C)). The percentage of cell viability was 
reduced as the concentration of boldine used to treat the cells 
increased. Higher concentrations of boldine gave a stronger 
inhibitory effect on the cell proliferation.
 Boldine was shown to exhibit stronger inhibitory 
effect on HCT 116 cells when the duration of treatment 
was longer (Figure 1(D)). The graph showed that there has 
been a marked decrease in the IC50 value of boldine across 
the period of incubation time. The lowest IC50 value of 
boldine on HCT 116, which was 22.4 ± 1.2 μg/mL at 72 
h, was chosen for subsequent experiments. Thus, for the 
subsequent experiments, HCT 116 cells were treated with 
22.4 μg/mL of boldine for 72 h.
BOLDINE CAUSES DOWN-REGULATION OF hTERT PROTEIN 
EXPRESSION IN HCT 116 CELLS
In order to determine the ability of boldine to down-
regulate hTERT protein expression in HCT 116 cells, cells 
were incubated in the absence and presence of boldine 
(22.4 μg/mL) for 72 h. Protein extracted from both treated 
and untreated cells were subjected to Western blotting. 
 As illustrated in Figure 2(A), the expression of 
β-Actin showed equal amounts of protein loaded in each 
lane. Thinner bands were observed in boldine treated 
cells compared to the control, indicating a pronounced 
reduction of hTERT protein in boldine-treated cells. The 
relative band intensities of control and boldine treated 
cells were quantified using ImageJ program. The average 
relative quantifications of control and boldine treated cells 
were 1.19 and 0.44, respectively, upon normalization with 
β-Actin. From this observation, exposure of HCT 116 cells 
to boldine decreased significantly the expression of hTERT 
proteins compared to the control (Figure 2(B)).
FIGURE 1. Percentage of cell viability and IC50 value of boldine against HCT 116 cells. Cells were seeded at 5×10
3 cells 
per well in 96-well plates for 24 h and the cells were treated with various concentration of boldine for (A) 24, (B) 48, 
and (C) 72 h. Results were expressed as percentage of cell viability as determined by SRB assay. All data shown are 
the means ± standard deviation (SD) of triplicates. Cell viability in boldine-treated cells was expressed as percentage 
of viable cells compared to control cells. Asterisk (*) indicated significant difference in treatments compared to control 
with p < 0.01 (D) HCT 116 cells (5×103 cells/well) were seeded in 96 well for 24 h and then treated with boldine (3.1-
100 μg/mL) at 3 different time points (24, 48 and 72 h). IC50 value was extrapolated from the graph of the percentage 
of inhibition against concentration of test sample. The IC50 value was presented as mean viability ± SD. 
Asterisk (*) indicated significant difference in each treatment p < 0.05 
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BOLDINE REDUCED hTERT AND hTERC mRNA         
EXPRESSION IN HCT 116 CELLS
The concentration, purity and integrity of RNA were 
quantified before qRT-PCR was carried out. In this 
experiment, it could be seen from the data in Table 1 
that the extracted RNA from both treated and untreated 
cells were considered as pure RNA without protein 
and guanidine salts contamination. As can be observed 
in Figure 3, two clear bands were visible on the gel, 
where the first band represented 28S and second 
band represented 18S rRNA, which indicated that no 
degradation occurred and high quality of RNA was 
obtained in each RNA sample. 
 The expression of hTERT and hTERC in control 
and treated samples were estimated in triplicates using 
qRT-PCR (Figure 4). Expression levels of hTERT and 
hTERC were normalized against β-Actin. The relative 
expression for both hTERT and hTERC were calculated 
using comparative Ct analysis. From the chart, qRT-
PCR analysis showed that hTERT and hTERC mRNA 
TABLE 1. RNA purity and concentration, extracted from both control and boldine treated cells
Sample A260/A280 A260/A230 Concentration (ng/μL)
C1
C2
C3
T1
T2
T3
2.106
2.106
2.090
2.063
2.122
2.110
2.117
1.824
2.214
2.266
2.251
2.095
263.381
221.046
99.797
462.118
618.017
270.085
HCT 116 cells were treated with 22.4 µg/mL of boldine for 72 h, followed by RNA extraction as described in the Materials and Methods. C: 
Control, T: Boldine treated cells
FIGURE 2. Effects of boldine on the levels of hTERT protein in HCT 116 cells. HCT 116 cells were treated with 
boldine (22.4 μg/mL) for 72 hours, and followed by protein extraction and Western blot analysis, (A) Blot for both 
control and boldine treated cells was shown and equivalent protein loading was confirmed by probing stripped blots 
for β-Actin, and (B) Average quantification of relative band intensities of control and boldine treated cells was shown 
after normalization to β-Actin signals. Images were quantified using ImageJ program. Data were presented 
as mean ± SD. Asterisk indicated significant difference compared to the control with p < 0.05
FIGURE 3. The integrity of RNA extracted from both 
control and boldine treated cells. Equal amount of RNA 
for control cells (C) and cells treated with 22.4 µg/mL 
of boldine for 72 h (T), were analysed using 1% native 
agarose gel stained with ethidium bromide
expression was down-regulated upon boldine treatment. 
The relative expressions of hTERT and hTERC on 
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boldine-treated cells were 0.97 and 0.78, respectively, 
compared to the control. Interestingly, the mRNA 
expression of hTERC was shown to be down-regulated 
significantly. In contrast, the down-regulation of hTERT 
mRNA was not significant compared to control upon 
boldine inhibition.
DISCUSSION
Several studies proposed that cancer cells exhibit higher 
telomerase activity while the telomerase activity in 
normal cells is barely detectable (Boscolo-Rizzo et al. 
2016; Makki 2015; Nakamura et al. 2010). Telomerase 
in cancer cells play an important role in lengthening 
the telomere in each round of cell division, allowing 
the cancer cells to escape senescence and achieve 
immortalization (Herbert et al. 1999; Xu et al. 2016). 
Thus, inhibiting telomerase expression in cancer cells 
is a promising approach in anticancer therapeutics. 
hTERT and hTERC, the subunit of telomerase are the 
rate-limiting components of telomerase catalytic activity 
(Cong et al. 2002). High level of hTERT and hTERC gene 
expression can be detected in a variety of human cancers. 
In most of the studies, inhibition of telomerase expression 
can be shown by the down-regulation of hTERT and 
hTERC genes expression.
 Nowadays, many natural compounds were tested and 
used to fight cancer. Boldine which is a natural alkaloid 
compound was shown to have anticancer properties, 
however, its anti-telomerase property was poorly 
understood. Recently, one of the boldine derivatives was 
found to have a strong ability in inhibiting telomerase by 
binding to the active site of TERT (Noureini et al. 2018). 
Furthermore, the ability of boldine to inhibit telomerase 
activity by down-regulating the expression of hTERT 
was shown in several studies (Noureini et al. 2015a, 
2015b). However, until recently, limited work was done 
in identifying the gene expression of hTERC in boldine 
treated cells, especially in HCT 116 cell line.
 In this study, 37.8±1.5 μg/mL of boldine was needed 
to reduce 50% of cell viability of HCT 116 in 48 h. Based 
on previous studies, 110±4.7 μM, 150±52 μM, and 160±4.5 
μM of boldine were needed to reduce 50% of the cell 
viability of HEK293, MDA-MB-231 and MCF-7 in 48 h, 
respectively (Noureini et al. 2015b). Boldine was showed 
to be cytotoxic to HCT 116 cell line, and the cytotoxic 
effect was almost similar to HEK293 cell line. Boldine also 
showed a time- and dose-dependent cytotoxicity on HCT 
116 cell line. This finding was in agreement with Noureini 
and Wink’s findings, which showed that boldine have a 
time- and dose-dependent inhibition of the proliferation 
of HepG-2 cells (Noureini et al. 2015a).
 The ability of boldine to down-regulate hTERT 
expression in this study was explored using Western blot 
technique and qRT-PCR. hTERT plays an important role 
in performing reverse transcription activity in telomerase 
(Shimojima et al. 2004). The hTERT gene expression was 
proposed to be regulated mainly at the transcriptional level 
(Günes et al. 2000). Therefore, besides hTERT protein 
expression, mRNA expression of hTERT was analyzed to 
further identify at which level of hTERT gene regulation 
was targeted by boldine in HCT 116 cell line. In the current 
study, it was shown that the transcript level of hTERT was 
slightly down-regulated, and the protein expression of 
hTERT was significantly reduced upon boldine treatment. 
This might be because of the involvement of other aspects 
of telomerase regulation, including alternative splicing 
(Noureini et al. 2015a). hTERT mRNA can often be spliced 
into non-functional isoforms, and only a smaller proportion 
of full length transcripts will be translated into functional 
hTERT protein (Wong et al. 2014). Since the probes used 
in this study were the probe that spans an exon junction 
specific for amplification of cDNA, it was believed that the 
hTERT isoform was amplified during real time PCR. Thus, 
the amplified hTERT isoform in this study represented a 
greater level of hTERT mRNA than would be needed to 
produce the observed hTERT protein in Western blotting.
The reduction in hTERT expression due to boldine 
treatment was further supported by Noureini and 
Tanavar’s experiment. They suggested that boldine 
inhibits telomerase activity mainly by reducing the mRNA 
expression of hTERT in MCF-7 cells (Noureini et al. 
FIGURE 4. Effects of boldine on the levels of hTERT and hTERC mRNA expression in HCT 
116 cells treated with boldine (22.4 μg/mL) for 72 h. Graph represented the relative mRNA 
expression of hTERT and hTERC in both control and boldine treated cells upon normalisation 
with endogenous control, β-Actin. The data were presented as mean ± SD. Asterisk indicated 
significant difference in treatments compared to controls with p < 0.05
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2015b). Other studies also claimed that the reduction of 
telomerase activity resulted from the down-regulation 
of hTERT mRNA levels in U937 cells and HepG-2 cells 
(Günes et al. 2000; Noureini et al. 2015b). As these studies 
proposed that the repression of telomerase activity was 
shown to be associated with the down-regulation of hTERT 
expression, the reduction of hTERT expression upon 
treatment with boldine was able to affect the telomerase 
expression in HCT 116 cell line.
 On the other hand, several studies suggested that the 
down-regulation of hTERT expression induced cellular 
apoptosis in various cancer cell types (Celeghin et al. 
2016; Chen et al. 2017). Telomerase inhibition through the 
mutant hTERT in human acute leukemia cells were able to 
induce apoptosis in the cells (Nakajima et al. 2003). Thus, 
the down-regulation of hTERT expression in this study 
might cause telomerase inhibition and apoptosis, hence 
reducing the proliferation of HCT 116 cells.
 Besides hTERT, hTERC is also a potential target for 
the down-regulation of telomerase activity as it functions 
as the template for elongation of telomeric repeat units 
(Cayuela et al. 2005). hTERC was ubiquitously expressed 
in cells, but the expression was five-fold higher in cancer 
cells (Avilion et al. 1996). In this present study, qRT-
PCR analysis of hTERC mRNA expression was down-
regulated upon boldine treatment. Although the level of 
hTERC was not significantly related with the telomerase 
activity, hTERC was indeed an important prerequisite for 
telomerase activity. It has been shown that there was no 
telomerase activity detected in the absence of hTERC (Feng 
et al. 1995). Furthermore, other studies showed that the 
reduction of hTERC expression resulted in reduced growth 
rate, cell cycle arrest and cell death in different types of 
cancer cell lines (Baena‐del Valle et al. 2018; Natarajan 
et al. 2004). From these studies, it was suggested that the 
down-regulation of hTERC expression was able to affect 
the telomerase expression, reduced cell proliferation and 
induced cell death in boldine-treated cells. As inhibition of 
hTERC expression was shown to be a powerful approach 
to inhibit the telomerase activity, it can be suggested that 
boldine could be a potential anti-telomerase based cancer 
therapy that can be further utilized in the future.
 More research is required to determine the efficacy 
of boldine towards cancer cell treatment. It would be 
interesting to assess the effects of boldine on telomerase 
activity in HCT 116 cells to correlate with the hTERT and 
hTERC gene expression assay. Apart from that, the details 
of regulation of telomerase splicing are still unknown. 
As the protein expression of hTERT was greatly reduced 
compared to the slightly down-regulated hTERT mRNA, 
boldine might affect the alternative splicing events. The 
identification of alternatively spliced isoform and detection 
of fusion transcript can also be done by performing 
next generation sequencing. Thus, further study can be 
conducted in order to investigate how gene regulation of 
hTERT has been affected by boldine in order to further 
validate the ability of boldine in reducing proliferation by 
targeting telomerase, especially in HCT 116 cells.
CONCLUSION
Boldine was shown to have a time- and dose- dependent 
cytotoxic effect on HCT 116 cells in this study. In addition, 
exposure to boldine induced down-regulation of hTERT 
and hTERC genes expression, as well as hTERT protein 
expression in HCT 116 cell line. From these findings, 
boldine might become a promising anti-telomerase 
compound towards HCT 116 cells. However, more research 
on this compound needs to be undertaken before the 
ability of boldine in targeting telomerase is more clearly 
understood and can be used as a therapeutic agent for the 
treatment of human colon carcinoma.
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